Lee Golden
Patrimonio netto: 6 M $ in data 31/05/2026
Patrimonio netto: 6 M $ in data 31/05/2026
Lee Scott Golden is currently an Independent Director at Cadrenal Therapeutics, Inc. since 2025 and Chief Medical Officer & Executive Vice President at PTC Therapeutics, Inc. since 2023.
Former roles include Medical Director at Pfizer Inc. from 2001 to 2005, Senior Director-US Medical at Actelion Pharmaceuticals US, Inc. from 2005 to 2008, Director at Coagulation Sciences LLC, Head-Cardiovascular & Blood Disorders at Eisai, Inc. from 2009 to 2011, Head-Pulmonary at Mesoblast Ltd. from 2011 to 2016, Chief Medical Officer at Gemphire Therapeutics, Inc. from 2016 to 2018, and Chief Medical Officer at Espero Pharmaceuticals, Inc. from 2018 to 2020.
Education includes undergraduate studies at the University of Michigan and a doctorate from New York University School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/04/2026 | 79.964 ( 0,1% ) | 6 M $ | 31/05/2026 | |
| 02/12/2025 | 1.667 ( 0,06% ) | 8 268 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PTC THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
| CADRENAL THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 24/11/2025 |
| Società | Posizione | Fine |
|---|---|---|
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Direttore Tecnico/Scientifico/R&S | 01/05/2020 |
| METAVIA INC. | Direttore Tecnico/Scientifico/R&S | 18/09/2018 |
| MESOBLAST LIMITED | Corporate Officer/Principal | 01/10/2016 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Corporate Officer/Principal | 01/07/2011 |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Corporate Officer/Principal | 01/03/2008 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mesoblast Ltd.
Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Health Technology |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coagulation Sciences LLC
Coagulation Sciences LLC Medical/Nursing ServicesHealth Services Provides blood-testing solutions | Health Services |
Gemphire Therapeutics, Inc.
Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for the treatment of Dyslipidemia | Health Technology |
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Distribution Services |
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale